Professor Zhijian Xiao has long been devoted to research on the molecular mechanisms underlying the pathogenesis of myeloid neoplasms (primarily myelodysplastic syndromes and myeloproliferative neoplasms) and novel clinical diagnosis and treatment strategies. As the project leader, he undertook 27 projects such as key and general programs of the National Natural Science Foundation of China, special programs for the healthcare industry, key and general programs of the Tianjin Natural Science Foundation, and the Innovation Team Program of the Chinese Academy of Medical Sciences. His research group has published nearly 390 papers in internationally renowned SCI-indexed journals such as the New England Journal of Medicine, Cancer Discovery, Blood, and Leukemia, as well as in domestic core journals like the Chinese Journal of Hematology. Their research findings have been cited by NCCN Guidelines, European ESMO Guidelines, and the WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Professor Xiao has spearheaded the development of 13 clinical guidelines/consensus documents for hematologic diseases in China and led the formulation of the "Diagnosis and Treatment Pathway for Myelodysplastic Syndromes" issued by the National Health Commission. He has established diagnostic, prognostic, and therapeutic systems for myelodysplastic syndromes and myeloproliferative neoplasms tailored to China's national conditions, which have been widely promoted and applied in China. These contributions have significantly advanced the precision diagnosis and standardized treatment of related diseases in China, earning high recognition from peer experts. Professor Xiao is a leading figure in the research field of myelodysplastic syndromes (MDS) and myeloproliferative neoplasms (MPN) in China.
Visiting scholar, Institute of Cancer Research, UK, 1999.12-2000.11
Visiting scholar, Kyoto University, Japan, 1998.3-1998.12
MD, Clinical medicine, Peking Union Medical College, Beijing, China, 1991-1995
BS, Clinical medicine, Hunan Medical University, Changsha, China, 1983-1988
Tenured Professor, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, 2022-
Director, Pathology Center, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences, 2020-
Vice Director, National Clinical Research Center for Blood Diseases, 2017-
Vice President, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences, 2013-
Vice Director, State Key Laboratory of Experimental Hematology, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences, 2002-2018
Chief Physician&Professor, MDS and MPN Centre, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences, 2001-
Director, MDS and MPN Centre, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences, 2000.12-
Director, Cord Blood Bank, Chinese Academy of Medical Sciences, 1999.1-1999.11
Deputy Chief Physician&Associate Professor, MDS and MPN Centre, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences, 1997-2001
Attending Physician, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences, 1995-1997
Resident Physician, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences, 1988-1991
PRINCIPAL HONORS, AWARDS:
2023 Haihe Medical Scholar
2020 Tianjin Famous Medical Doctor
2014 National Outstanding Scientific and Technological Worker
2012 State Council "Government Special Allowance Expert"
2009 National Candidate for "New Century Talent Project"
2006 "New Century Excellent Talent Support Program" of the Ministry of Education
2005-2006 "Outstanding Young and Middle-aged Expert" of the Ministry of Health
MAJOR NATIONAL LEADERSHIP POSITIONS, SOCIETIES AND BOARDS:
2020-present Associate Editor, Chinese Journal of Hematology
2017-2020 Editorial Board Member, Gene,Chromosomes and Cancer
2015-present Associate Editor, International Journal of Blood Transfusion and Hematology
2015-present Associate Editor, Journal of Leukemia and Lymphoma
2014-present Editorial Board Member, Blood Reviews
2014-2018 Editorial Board Member, Acta Haematologica
2022-present President, The 2nd Hematologic Oncology Professional Committee, Tianjin Anti-Cancer Association
2022-present Vice President, The 1st Oncology Clinical Research Management Professional Committee, Chinese Anti-Cancer Association
2020-2023 Vice President, The 3rd Hematology Committee, Cross-Strait Medical and Health Exchange Association
2020-present Group Leader, Leukemia & Lymphoma Working Group, The 11th Committee of Hematology Society, Chinese Medical Association
2019-present Vice president, The 11th Hematology Branch of Chinese Medical Association
2019-2021 Vice chairman, The 1st Board China Hematology Specialist Alliance
2019-2022 Vice Group Leader, Myeloid Malignancies Group, The 5th Hematological Malignancies Committee, China Anti-cancer Association
2019-present Group Leader, MDS and MPN Group, The 2nd Hematological Malignancies Committee, China Anti-cancer Association.
2018-2020 Vice president, Anti-leukemia Alliance, Chinese Society of Clinical Oncology
SELECTED PUBLICATIONS:
1. Bao Z, Li B, Qin T, Xu Z, Qu S, Jia Y, Li C, Pan L, Gao Q, Jiao M, Wang H, Sun Q, Xiao Z*. Molecular characteristics and clinical implications of TP53 mutations in therapy-related myelodysplastic syndromes. Blood Cancer J.2025;15(1):58.
2. Li F, Qin T, Li B, Qu S, Pan L, Zhang P, Sun Q, Cai W, Gao Q, Jiao M, Li J, Ai X, Ma J, Gale RP, Xu Z*, Xiao Z*. Predicting survival in patients with myelodysplastic/myeloproliferative neoplasms with SF3B1 mutation and thrombocytosis. Leukemia. 2024;38(6):1334-1341.
3. Yan X, Xu Z, Zhang P, Sun Q, Jia Y, Qin T, Qu S, Pan L, Li Z, Liu J, Song Z, Gao Q, Jiao M, Gong J, Wang H, Li B*, Xiao Z*. Non-driver mutations landscape in different stages of primary myelofibrosis determined ASXL1 mutations play a critical role in disease progression. Blood Cancer J. 2023;13(1):56.
4. Zhang Y#, Wu J#, Qin T, Xu Z, Qu S, Pan L, Li B, Wang H, Zhang P, Yan X, Gong J, Gao Q, Gale RP, Xiao Z*. Comparison of the revised 4th (2016) and 5th (2022) editions of the World Health Organization classification of myelodysplastic neoplasms. Leukemia. 2022;36(12):2875-2882.
5. Liu YC#, Kwon J#, Fabiani E#, Xiao Z#, Liu YV, Follo MY, Liu J, Huang H, Gao C, Liu J, Falconi G, Valentini L, Gurnari C, Finelli C, Cocco L, Liu JH, Jones AI, Yang J, Yang H, Thoms JAI, Unnikrishnan A, Pimanda JE, Pan R, Bassal MA, Voso MT, Tenen DG*, Chai L*. Demethylation and Up-Regulation of an Oncogene after Hypomethylating Therapy. N Engl J Med. 2022;386(21):1998-2010.
6. Liu D, Li B, Xu Z, Zhang P, Qin T, Qu S, Pan L, Sun X, Shi Z, Huang H, Wang H, Gale RP, Xiao Z*. RBC distribution width predicts thrombosis risk in polycythemia vera. Leukemia. 2022;36(2):566-568.
7. Liu D, Xu Z, Zhang P, Qin T, Li B, Qu S, Pan L, Cai W, Liu J, Wang H, Sun Q, Sun X, Jiao M, Gao Q, Shi Z, Huang H, Huang G, Gale RP, Xiao Z*. Iron deficiency in JAK2 exon12 and JAK2-V617F mutated polycythemia vera. Blood Cancer J. 2021;11(9):154.
8. Huang H#, Xu C#, Gao J#, Li B, Qin T, Xu Z, Ren S, Zhang Y, Jiao M, Qu S, Pan L, Hu N, Liu J, Cai W, Zhang Y, Wu D, Zhang P, Gale RP, Huang G, Zhou J, Shi L*, Xiao Z*. Severe ineffective erythropoiesis discriminates prognosis in myelodysplastic syndromes: analysis based on 776 patients from a single centre. Blood Cancer J. 2020;10(8):83.
9. Hayashi Y#, Zhang Y#, Yokota A#, Yan X, Liu J, Choi K, Li B, Sashida G, Peng Y, Xu Z, Huang R, Zhang L, Freudiger GM, Wang J, Dong Y, Zhou Y, Wang J, Wu L, Bu J, Chen A, Zhao X, Sun X, Chetal K, Olsson A, Watanabe M, Romick-Rosendale LE, Harada H, Shih LY, Tse W, Bridges JP, Caligiuri MA, Huang T, Zheng Y, Witte DP, Wang QF, Qu CK, Salomonis N, Grimes HL, Nimer SD, Xiao Z*, Huang G*. Pathobiologic Pseudohypoxia as a Putative Mechanism Underlying Myelodysplastic Syndromes. Cancer Discov, 2018; 8(11):1438-1457
10. Luo X#, Xu Z#, Li B#, Qin T, Zhang P, Zhang H, Fang L, Pan L, Hu N, Qu S, Zhang Y, Huang G, Peter Gale R, Xiao Z*. Thalidomide plus prednisone with or without danazol therapy in myelofibrosis: a retrospective analysis of incidence and durability of anemia response. Blood Cancer J,2018;8(1):9.
11. Li B, Gale RP, Xu Z, Qin T, Song Z, Zhang P, Bai J, Zhang L, Zhang Y, Liu J, Huang G, Xiao Z*. Non-driver mutations in myeloproliferative neoplasm-associated myelofibrosis. J Hematol Oncol, 2017;10(1):99
12. Li B#, Zhang P3, Feng G, Xu Z, Qin T, Zhang Y, Sha Z, Dong D, Zhang H, Fang L, Pan L, Hu N, Qu S, Cai W, Huang G, Xiao Z. Bone marrow fibrosis grade is an independent risk factor for overall survival in patients with primary myelofibrosis. Blood Cancer J. 2016;6(12):e505.
13. Li B, Gale R, Xiao Z*. Molecular genetics of chronic neutrophilic leukemia, chronic myelomonocytic leukemia and atypical chronic myeloid leukemia. J Hematol Oncol. 2014;7:93.
14. Cui Y, Li B, Gale R, Jiang Q, Xu Z, Qin T, Zhang P, Zhang Y, Xiao Z*. CSF3R, SETBP1 and CALR mutations in chronic neutrophilic leukemia. J Hematol Oncol. 2014;7:77.
15. Wang J#, Xu Z#, Liu L#, Gale RP, Cross NC, Jones AV, Qin T, Ai X, Xu J, Zhang T, Sun X, Li Q, Zhang P, Zhang Y, Xiao Z*. JAK2V617F allele burden, JAK2 46/1 haplotype and clinical features of Chinese with myeloproliferative neoplasms. Leukemia. 2013; 27(8):1763-1767
16. Xu Z, Gale RP, Zhang Y, Qin T, Chen H, Zhang P, Zhang T, Liu L, Qu S, Xiao Z*. Unique features of primary myelofibrosis in Chinese. Blood. 2012; 119(11):2469-2473